“Ten to one they're all low-balling it.” Mo
Post# of 148288
(Total Views: 618)
Posted On: 10/01/2020 10:00:05 PM
“Ten to one they're all low-balling it.”
More likely scenario is that NP is asking for far too much. The market determines a biotech company’s value based on the pipeline and data, not on potential indications with only animal or human cell testing. I don’t recall a BO of a biotech by a BP that was 10x the current market value, or whatever NP believes the SP should be that day ($10, $25, $150, $1,000).
IMO, NP’s plan is to get ONE approval and then sell the company. Right now, COVID and HIV are the only near term targets as neither cancer trial won’t complete until 2022, NASH hasn’t started and will take time to enroll, and even the potential Alzheimer’s trial will take time to enroll and complete. IMO, COVID could do it but no combo (because of Vyera and the barriers to combo market penetration aka Vyera).
The DSMC better come through.
More likely scenario is that NP is asking for far too much. The market determines a biotech company’s value based on the pipeline and data, not on potential indications with only animal or human cell testing. I don’t recall a BO of a biotech by a BP that was 10x the current market value, or whatever NP believes the SP should be that day ($10, $25, $150, $1,000).
IMO, NP’s plan is to get ONE approval and then sell the company. Right now, COVID and HIV are the only near term targets as neither cancer trial won’t complete until 2022, NASH hasn’t started and will take time to enroll, and even the potential Alzheimer’s trial will take time to enroll and complete. IMO, COVID could do it but no combo (because of Vyera and the barriers to combo market penetration aka Vyera).
The DSMC better come through.
(2)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼